APO Research
Talk to an analyst

APO RESEARCH · REPORT

KI-67 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global KI-67 Antibody Market Outlook and Growth Opportunities 2026

19 December 2025193 pages

Choose your research edition.

Industry ResearchKI-67 Antibody Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal KI-67 Antibody Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal KI-67 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal KI-67 Antibody Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal KI-67 Antibody Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global KI-67 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for KI-67 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for KI-67 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for KI-67 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the KI-67 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the KI-67 Antibody market include Atlas Antibodies, BD Biosciences, Beckman Coulter, Bio-Rad, FineTest, Leica Biosystems, Miltenyi Biotec, Miltenyi Biotec and NSJ Bioreagents, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global KI-67 Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of KI-67 Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents KI-67 Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global KI-67 Antibody market.

KI-67 Antibody Segment by Company

Atlas Antibodies

BD Biosciences

Beckman Coulter

Bio-Rad

FineTest

Leica Biosystems

Miltenyi Biotec

Miltenyi Biotec

NSJ Bioreagents

Proteintech

Synaptic

United States Biological

Merck

Thermo Fisher Scientific

KI-67 Antibody Segment by Type

Polyclonal

Monoclonal

KI-67 Antibody Segment by Application

Immunohistochemistry Paraffin

Immunohistochemistry Frozen

Immunofluorescence

Western Blot

Others

KI-67 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global KI-67 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the KI-67 Antibody key companies, revenue, market share, and recent developments.

3. To split the KI-67 Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions KI-67 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify KI-67 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze KI-67 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global KI-67 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of KI-67 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of KI-67 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global KI-67 Antibody industry.

Chapter 3: Detailed analysis of KI-67 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of KI-67 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of KI-67 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. KI-67 Antibody Industry Trends Table 2. KI-67 Antibody Industry Drivers Table 3. KI-67 Antibody Industry Opportunities and Challenges Table 4. KI-67 Antibody Industry Restraints Table 5. Global KI-67 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global KI-67 Antibody Revenue Share by Company (2021-2026) Table 7. Global KI-67 Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global KI-67 Antibody Key Company Manufacturing Base & Headquarters Table 9. Global KI-67 Antibody Company, Product Type & Application Table 10. Global KI-67 Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global KI-67 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global KI-67 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global KI-67 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global KI-67 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global KI-67 Antibody Sales Value Share by Type (2021-2026) Table 20. Global KI-67 Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Immunohistochemistry Paraffin Table 22. Significant Companies of Immunohistochemistry Frozen Table 23. Significant Companies of Immunofluorescence Table 24. Significant Companies of Western Blot Table 25. Significant Companies of Others Table 26. Global KI-67 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global KI-67 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global KI-67 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global KI-67 Antibody Sales Value Share by Application (2021-2026) Table 30. Global KI-67 Antibody Sales Value Share by Application (2027-2032) Table 31. Global KI-67 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global KI-67 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global KI-67 Antibody Sales Value Share by Region (2021-2026) Table 34. Global KI-67 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global KI-67 Antibody Sales Value Share by Region (2027-2032) Table 36. Global KI-67 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global KI-67 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global KI-67 Antibody Sales Value Market Share by Country (2021-2026) Table 39. Global KI-67 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global KI-67 Antibody Sales Value Market Share by Country (2027-2032) Table 41. Atlas Antibodies Company Information Table 42. Atlas Antibodies Business Overview Table 43. Atlas Antibodies KI-67 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Atlas Antibodies KI-67 Antibody Product Portfolio Table 45. Atlas Antibodies Recent Development Table 46. BD Biosciences Company Information Table 47. BD Biosciences Business Overview Table 48. BD Biosciences KI-67 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. BD Biosciences KI-67 Antibody Product Portfolio Table 50. BD Biosciences Recent Development Table 51. Beckman Coulter Company Information Table 52. Beckman Coulter Business Overview Table 53. Beckman Coulter KI-67 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Beckman Coulter KI-67 Antibody Product Portfolio Table 55. Beckman Coulter Recent Development Table 56. Bio-Rad Company Information Table 57. Bio-Rad Business Overview Table 58. Bio-Rad KI-67 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Bio-Rad KI-67 Antibody Product Portfolio Table 60. Bio-Rad Recent Development Table 61. FineTest Company Information Table 62. FineTest Business Overview Table 63. FineTest KI-67 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. FineTest KI-67 Antibody Product Portfolio Table 65. FineTest Recent Development Table 66. Leica Biosystems Company Information Table 67. Leica Biosystems Business Overview Table 68. Leica Biosystems KI-67 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Leica Biosystems KI-67 Antibody Product Portfolio Table 70. Leica Biosystems Recent Development Table 71. Miltenyi Biotec Company Information Table 72. Miltenyi Biotec Business Overview Table 73. Miltenyi Biotec KI-67 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Miltenyi Biotec KI-67 Antibody Product Portfolio Table 75. Miltenyi Biotec Recent Development Table 76. Miltenyi Biotec Company Information Table 77. Miltenyi Biotec Business Overview Table 78. Miltenyi Biotec KI-67 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Miltenyi Biotec KI-67 Antibody Product Portfolio Table 80. Miltenyi Biotec Recent Development Table 81. NSJ Bioreagents Company Information Table 82. NSJ Bioreagents Business Overview Table 83. NSJ Bioreagents KI-67 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. NSJ Bioreagents KI-67 Antibody Product Portfolio Table 85. NSJ Bioreagents Recent Development Table 86. Proteintech Company Information Table 87. Proteintech Business Overview Table 88. Proteintech KI-67 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Proteintech KI-67 Antibody Product Portfolio Table 90. Proteintech Recent Development Table 91. Synaptic Company Information Table 92. Synaptic Business Overview Table 93. Synaptic KI-67 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Synaptic KI-67 Antibody Product Portfolio Table 95. Synaptic Recent Development Table 96. United States Biological Company Information Table 97. United States Biological Business Overview Table 98. United States Biological KI-67 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. United States Biological KI-67 Antibody Product Portfolio Table 100. United States Biological Recent Development Table 101. Merck Company Information Table 102. Merck Business Overview Table 103. Merck KI-67 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Merck KI-67 Antibody Product Portfolio Table 105. Merck Recent Development Table 106. Thermo Fisher Scientific Company Information Table 107. Thermo Fisher Scientific Business Overview Table 108. Thermo Fisher Scientific KI-67 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Thermo Fisher Scientific KI-67 Antibody Product Portfolio Table 110. Thermo Fisher Scientific Recent Development Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. KI-67 Antibody Product Image Figure 2. Global KI-67 Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global KI-67 Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global KI-67 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global KI-67 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global KI-67 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global KI-67 Antibody Sales Value Share by Type (2021-2032) Figure 12. Immunohistochemistry Paraffin Image Figure 13. Immunohistochemistry Frozen Image Figure 14. Immunofluorescence Image Figure 15. Western Blot Image Figure 16. Others Image Figure 17. Global KI-67 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global KI-67 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global KI-67 Antibody Sales Value Share by Application (2021-2032) Figure 20. Global KI-67 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global KI-67 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America KI-67 Antibody Sales Value (2021-2032) & (US$ Million) Figure 23. North America KI-67 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe KI-67 Antibody Sales Value (2021-2032) & (US$ Million) Figure 25. Europe KI-67 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific KI-67 Antibody Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific KI-67 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America KI-67 Antibody Sales Value (2021-2032) & (US$ Million) Figure 29. South America KI-67 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa KI-67 Antibody Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa KI-67 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt KI-67 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt KI-67 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt KI-67 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunohistochemistry Paraffin
  • Immunohistochemistry Frozen
  • Immunofluorescence
  • Western Blot
  • Others
Companies covered
  • Atlas Antibodies
  • BD Biosciences
  • Beckman Coulter
  • Bio-Rad
  • FineTest
  • Leica Biosystems
  • Miltenyi Biotec
  • Miltenyi Biotec
  • NSJ Bioreagents
  • Proteintech
  • Synaptic
  • United States Biological
  • Merck
  • Thermo Fisher Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global KI-67 Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global KI-67 Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 KI-67 Antibody Market Dynamics
  1. 2.1 KI-67 Antibody Industry Trends
  2. 2.2 KI-67 Antibody Industry Drivers
  3. 2.3 KI-67 Antibody Industry Opportunities and Challenges
  4. 2.4 KI-67 Antibody Industry Restraints
3 KI-67 Antibody Market by Company
  1. 3.1 Global KI-67 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global KI-67 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global KI-67 Antibody Company Ranking (2024-2026)
  4. 3.4 Global KI-67 Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global KI-67 Antibody Company Product Type and Application
  6. 3.6 Global KI-67 Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global KI-67 Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 KI-67 Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 KI-67 Antibody Market by Type
  1. 4.1 KI-67 Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global KI-67 Antibody Sales Value by Type
  5. 4.2.1 Global KI-67 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global KI-67 Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global KI-67 Antibody Sales Value Share by Type (2021-2032)
5 KI-67 Antibody Market by Application
  1. 5.1 KI-67 Antibody Application Introduction
  2. 5.1.1 Immunohistochemistry Paraffin
  3. 5.1.2 Immunohistochemistry Frozen
  4. 5.1.3 Immunofluorescence
  5. 5.1.4 Western Blot
  6. 5.1.5 Others
  7. 5.2 Global KI-67 Antibody Sales Value by Application
  8. 5.2.1 Global KI-67 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global KI-67 Antibody Sales Value by Application (2021-2032)
  10. 5.2.3 Global KI-67 Antibody Sales Value Share by Application (2021-2032)
6 KI-67 Antibody Regional Value Analysis
  1. 6.1 Global KI-67 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global KI-67 Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global KI-67 Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global KI-67 Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America KI-67 Antibody Sales Value (2021-2032)
  7. 6.3.2 North America KI-67 Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe KI-67 Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe KI-67 Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific KI-67 Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific KI-67 Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America KI-67 Antibody Sales Value (2021-2032)
  16. 6.6.2 South America KI-67 Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa KI-67 Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa KI-67 Antibody Sales Value Share by Country, 2025 VS 2032
7 KI-67 Antibody Country-level Value Analysis
  1. 7.1 Global KI-67 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global KI-67 Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global KI-67 Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global KI-67 Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA KI-67 Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada KI-67 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico KI-67 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany KI-67 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France KI-67 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. KI-67 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy KI-67 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain KI-67 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia KI-67 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands KI-67 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries KI-67 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China KI-67 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan KI-67 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea KI-67 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India KI-67 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia KI-67 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia KI-67 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil KI-67 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina KI-67 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile KI-67 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia KI-67 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru KI-67 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia KI-67 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel KI-67 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE KI-67 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey KI-67 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran KI-67 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt KI-67 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt KI-67 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt KI-67 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Atlas Antibodies
  2. 8.1.1 Atlas Antibodies Company Information
  3. 8.1.2 Atlas Antibodies Business Overview
  4. 8.1.3 Atlas Antibodies KI-67 Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Atlas Antibodies KI-67 Antibody Product Portfolio
  6. 8.1.5 Atlas Antibodies Recent Developments
  7. 8.2 BD Biosciences
  8. 8.2.1 BD Biosciences Company Information
  9. 8.2.2 BD Biosciences Business Overview
  10. 8.2.3 BD Biosciences KI-67 Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BD Biosciences KI-67 Antibody Product Portfolio
  12. 8.2.5 BD Biosciences Recent Developments
  13. 8.3 Beckman Coulter
  14. 8.3.1 Beckman Coulter Company Information
  15. 8.3.2 Beckman Coulter Business Overview
  16. 8.3.3 Beckman Coulter KI-67 Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Beckman Coulter KI-67 Antibody Product Portfolio
  18. 8.3.5 Beckman Coulter Recent Developments
  19. 8.4 Bio-Rad
  20. 8.4.1 Bio-Rad Company Information
  21. 8.4.2 Bio-Rad Business Overview
  22. 8.4.3 Bio-Rad KI-67 Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bio-Rad KI-67 Antibody Product Portfolio
  24. 8.4.5 Bio-Rad Recent Developments
  25. 8.5 FineTest
  26. 8.5.1 FineTest Company Information
  27. 8.5.2 FineTest Business Overview
  28. 8.5.3 FineTest KI-67 Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 FineTest KI-67 Antibody Product Portfolio
  30. 8.5.5 FineTest Recent Developments
  31. 8.6 Leica Biosystems
  32. 8.6.1 Leica Biosystems Company Information
  33. 8.6.2 Leica Biosystems Business Overview
  34. 8.6.3 Leica Biosystems KI-67 Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Leica Biosystems KI-67 Antibody Product Portfolio
  36. 8.6.5 Leica Biosystems Recent Developments
  37. 8.7 Miltenyi Biotec
  38. 8.7.1 Miltenyi Biotec Company Information
  39. 8.7.2 Miltenyi Biotec Business Overview
  40. 8.7.3 Miltenyi Biotec KI-67 Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Miltenyi Biotec KI-67 Antibody Product Portfolio
  42. 8.7.5 Miltenyi Biotec Recent Developments
  43. 8.8 Miltenyi Biotec
  44. 8.8.1 Miltenyi Biotec Company Information
  45. 8.8.2 Miltenyi Biotec Business Overview
  46. 8.8.3 Miltenyi Biotec KI-67 Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Miltenyi Biotec KI-67 Antibody Product Portfolio
  48. 8.8.5 Miltenyi Biotec Recent Developments
  49. 8.9 NSJ Bioreagents
  50. 8.9.1 NSJ Bioreagents Company Information
  51. 8.9.2 NSJ Bioreagents Business Overview
  52. 8.9.3 NSJ Bioreagents KI-67 Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 NSJ Bioreagents KI-67 Antibody Product Portfolio
  54. 8.9.5 NSJ Bioreagents Recent Developments
  55. 8.10 Proteintech
  56. 8.10.1 Proteintech Company Information
  57. 8.10.2 Proteintech Business Overview
  58. 8.10.3 Proteintech KI-67 Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Proteintech KI-67 Antibody Product Portfolio
  60. 8.10.5 Proteintech Recent Developments
  61. 8.11 Synaptic
  62. 8.11.1 Synaptic Company Information
  63. 8.11.2 Synaptic Business Overview
  64. 8.11.3 Synaptic KI-67 Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Synaptic KI-67 Antibody Product Portfolio
  66. 8.11.5 Synaptic Recent Developments
  67. 8.12 United States Biological
  68. 8.12.1 United States Biological Company Information
  69. 8.12.2 United States Biological Business Overview
  70. 8.12.3 United States Biological KI-67 Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 United States Biological KI-67 Antibody Product Portfolio
  72. 8.12.5 United States Biological Recent Developments
  73. 8.13 Merck
  74. 8.13.1 Merck Company Information
  75. 8.13.2 Merck Business Overview
  76. 8.13.3 Merck KI-67 Antibody Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Merck KI-67 Antibody Product Portfolio
  78. 8.13.5 Merck Recent Developments
  79. 8.14 Thermo Fisher Scientific
  80. 8.14.1 Thermo Fisher Scientific Company Information
  81. 8.14.2 Thermo Fisher Scientific Business Overview
  82. 8.14.3 Thermo Fisher Scientific KI-67 Antibody Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Thermo Fisher Scientific KI-67 Antibody Product Portfolio
  84. 8.14.5 Thermo Fisher Scientific Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst